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The MphR(A) transcriptional repressor protein was incorporated into high-efficiency ex-
pression vectors, purified and characterized.  Initial screens for crystallography solvents 
were conducted along with preliminary gel-shift and intrinsic fluorescence quenching ex-
periments to obtain the equilibrium dissociation constant for the protein-DNA interac-
tions.  The constant was found to be 0.5 – 1.9 M, depending on the method used.  The 
gene was also incorporated into positive feedback circuits to detect macrolide antibiotics 
using various reporter genes and plasmid constructs.  Qualitatively, the circuits showed a 
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Chapter 1: Introduction 
1.1: Basic Protein Information 
 The Macrolide 2’-Phosphotransferase I [Mph(A)] protein isolated from Es-
cherichia coli is a strong inactivator of macrolide antibiotics, such as erythromycin 
(Erm)1.  This protein is induced by Erm in the natural strain (Figure 1-1) through the tran-
scriptional repressor protein, MphR(A)2.  Specifically, the repressor controls transcription 
of a gene sequence containing the mph(A)-mrx-mphR(A) operon, in which Mrx has an 
unidentified function3.  The negative transcription factor, MphR(A), has only been 
crudely characterized, but presents a significant possibility for use in genetically encoded 
erythromycin sensing feedback loops. 
 
 MphR can be included in a large family of transcriptional repressors responsive to 
molecules present in the bacterial system4.  The most widely characterized of these rep-
ressors is TetR, which binds as a homodimer to a specific sequence of DNA that regu-
lates the formation of tetracycline (Tc) in the cell.  TetR is inducible by tetracycline, such 
that when the [TcMg]+ complex binds the protein, a conformational change occurs and 
the protein dissociates from the DNA. 
 





1.2: TetR Family of Transcriptional Regulators 
1.2.1: Key Features 
 There are a number of features of MphR that appear to be consistent amongst a 
majority of similar transcriptional repressors4.  The most important feature of the protein 
itself is the HTH motif.  The sequence of -helix-turn--helix is extremely highly con-
served among members of this family, although it has been shown to appear mainly in the 
N-terminal region and occasionally in the C-terminal region of the primary sequence4.  
Additionally, the residues present in the HTH regions of the primary sequence are them-
selves highly conserved among these proteins. 
 Another feature of these protein-DNA interactions is the nature of the DNA se-
quence involved in protein recognition.  Often, these sequences are palindromic or 
pseudo-palindromic—that is, they contain a complete or nearly complete inverse repeat at 
the protein binding site.  This is further evidence to support the idea that these proteins 
tend to bind as some sort of oligomer. 
 An example of a protein with similar function is QacR regulator.  This protein is 
responsive to a large library of drugs4.  It regulates transcription of the quaternary ammo-
nium compound resistance gene and thus must bind to a variety of drugs instead of just 
one, like TetR.  The interactions between QacR and DNA are also different than TetR; a 
pair of dimers binds the palindromic sequence.  However, the regions of the HTH motif 





1.2.2: Sequence Homology 
 A BLAST search using ClustalW shows a high degree of sequence homology be-
tween MphR and other prominent members of the TetR family (Figure 1-2), particularly 
with the HTH motif in the N-terminal region. 
 
1.3: Regulatory Circuits and Biofeedback Loops 
1.3.1: General Concept 
 In general, there are two types of biological response networks.  Positive feedback 
involves an increase in some response variable, while negative feedback shows a de-
crease in the response variable.  Feedback loops have evolved to cause a variety of re-
sponses.  One of the most studied of these loops involves the p53 regulatory system in-
volved in cell death5.  Through an extensive list of possible activators and a somewhat 
complex response system involving many other intermediary proteins, a response from 
the p53 protein can be seen in cells of almost every possible function.  Activation of the 
Figure 1-2: ClustalX 2 Alignment of MphR with TetR Family Members 
 




p53 prevents the transcription of some genes and allows for the transcription of a number 
of other genes including the MDM-2 protein, which is, in turn, the major negative regula-
tor of p53 (Figure 1-3).  Any of a multitude of other proteins can act on some aspect of 
this circuit either increasing or decreasing the effect of p53. 
 
 According to Sayut, et al.6 and others7-9 many of these positive feedback loops 
exhibit “switch-like all-or-none bistability” which means that they have a binary response 
to the particular inducer of interest.  Bistability requires some degree of ultrasensitivity to 
the inducer, although the property is not required for a working feedback loop.  However, 
designing and engineering a loop to be bistable will give the most useful results. 
 There are a number of advantages to using positive feedback loops to control gene 
expression.  First, the binary activity means that the gene can be controlled simply and 
with tight regulation.  Second, since many of the repressor proteins used to control the 
loops are derived from bacterial sources, they have the added advantage of being easily 
inducible by simple antibiotics and they are nontoxic to the host cells6. 
1.3.2: TetR Family Constructs 
 The TetR family of transcriptional repressors is also generally involved in regula-
tory circuits.  As described for both TetR and QacR, above, the induction of the repressor 
protein is done by a molecule or set of molecules, the presence of which depends on the 






binding equilibrium of that particular protein.  Specifically, when TetR is bound to the 
DNA it prevents transcription of the protein that removes tetracycline from the cell, as 
well as its own transcription.  When no Tc is present in the cell, there is no need for the 
protein to remove it from the cell, therefore TetR remains bound to the promoter se-
quence.  By controlling its own transcription, TetR ensures that, after Tc has been added 
to the system, there will still be some protein that is not part of the TetR-TcMg complex 
and can therefore re-regulate the transcription of the TetA protein (Figure 1-4). 
 
 TetR, among other members of this family have already been employed exten-
sively in biotechnological applications that take advantage of their properties as self-
regulatory4.  Their use provides hope that, after characterization, MphR will be useful for 
analogous applications.  In theory, any member of the TetR family of transcriptional rep-
ressors could be used in some feedback loop.  In practice, however, this is not always 
possible.  Many of these transcriptional effectors are involved in very complex regulatory 
systems4 and would therefore be difficult to control externally.  The complex systems 
would also present a problem when trying to determine which stage of the circuit is di-
rectly affected upon changes to the system.  Some of these networks are comprised of 







simple sequential controls and therefore have been studied and utilized to a great extent.  
In particular, the LuxR activator system has been investigated in many studies because of 
its natural, quorum-sensing properties6.  This circuit (Figure 1-5) has also been shown to 
have significant potential in synthetic biology10. 
 
 In nature, the LuxR activator is required for expression of the luciferase operon 
responsible for luminescence in Vibrio harveyi bacteria4.  As a quorum-sensing protein, 
LuxR is responsive to a compound secreted from other bacteria, 3-oxo-hexanoyl-
homoserine lactone.  Sayut, et al.6 used circuits shown to investigate the effect that mu-
tant protein would have on the response of the system.  They were interested in whether 
or not the sensitivity of the system could be improved by introducing mutations, which 
they did using error-prone PCR.  They scanned the resultant library of mutants for re-
sponse in the feedback loops showing that by enhancing the response to the intended in-
ducer, the response of a feedback loop could be improved to require less inducer for acti-
vation. 







1.3.3: MphR Constructs 
 In the case of MphR(A), like the majority of the TetR family of proteins, the cir-
cuit would involve positive feedback.  Specifically, cells are engineered to make the 
MphR(A) protein independent of the presence of erythromycin.  This protein can then 
bind to the native promoter sequence, as described above, which controls transcription of 
a specific reporter protein.  In many cases, the GFPuv or -Lactamase activity are used 
since their presence can be measured spectroscopically (Figure 1-6).  The specific in-
ducer—for MphR(A), erythromycin would be used—is then introduced to the system in 
some way resulting in increased reporter activity, which can be measured as a function of 
the amount of inducer in the system. 
 
 Circuits under the control of MphR with other reporters have been assembled11.  
The authors describe a luciferase-based sensor that can detect the presence of erythromy-
Figure 1-6: Basic Illustration of Potential MphR Circuits 
 
PmphR is the DNA sequence recognized by MphR as found by Noguchi, et al.3 and de-
scribed below.  PlacIq is the constitutive sequence of the lacI promoter.  pBAD is the arabi-
nose-inducible araBAD promoter.  GFPuv is the gene encoding the Green Fluorescent Pro-
tein; LacZ is the gene encoding -Galactosidase enzyme, and CATUPP is a gene that en-
codes the chloramphenicol acyltransferase and uracil phosphoribosyltransferase enzymes, 




cin and other macrolides as directly delivered or as produced by bacteria that biosynthe-
size them.  The work confirms the low specificity of wild-type MphR-based circuits, but 
presents promising results for quantifiable circuit assembly. 
1.4: MphR Biochemistry 
1.4.1: DNA Binding 
 Noguchi, et al.3 performed crude analyses to determine the exact location of bind-
ing to the promoter region of the mph(A) gene.  They found a partially overlapping re-
gion of 30 nucleotides on the coding strand and 29 nucleotides on the complementary 
strand to be protected by MphR(A) from DNase I footprinting.  The net 35 base pairs 
protected encompass exactly the promoter sequence for transcription of the mph(A) gene. 
1.4.2: Inducer Sensitivity 
 MphR(A) is known to be inducible by erythromycin (Erm)2.  In order to deter-
mine whether or not other macrolides could also induce transcription, Noguchi, et al.3 
also investigated binding of oleandomycin, josamycin, and kitasamycin to MphR(A).  
These compounds, which show a high degree of similarity to erythromycin (Figure 1-7), 
were all shown to induce the release of MphR(A) from its promoter.  The relatively low 
specificity greatly limits the potential of this system for use in feedback loops.  However, 
the group made no effort to quantify any binding interactions or ascertain the nature of 
inducer binding.  That is, no information regarding which structural features—the macro-
cycle, sugars, etc.—of the macrolide contact the protein. 
 Response to a variety of inducers is not unusual.  Many transcriptional repressors 




MarR12, 13, which is highly homologous to MphR(A).  Some work by Vazquez-Laslop, et 
al.14 has shown that when the structurally different ligands bind to BmrR, they make spe-
cific contacts with different residues in the binding pocket.  Therefore, simple mutations 
to some of these residues will inherently preclude specific inducers from making contact 
with the protein increasing the specificity for the desired drug.  Solving this problem is 
not so easy for MphR(A); the structural similarity between the macrolides that have al-
ready been shown to inactivate the protein would suggest that they contact similar resi-
dues in the binding pocket. 
 
 Unfortunately, since bistability is an important feature governing the usefulness of 
a particular feedback loop, the wild-type MphR(A) protein is not inherently useful.  A 
variety of similar macrolides can bind the protein, inducing its release from the DNA 














































































with approximately the same affinity3 and relatively low selectivity for any one of the 
compounds.  Conveniently, quite a bit of work has been done engineering specific mu-
tants of similar proteins that have improved specificity for one inducer.  In some cases, 
mutants have even been developed that recognize a completely different inducer15. 
1.5: Improving Specificity by Site-Directed Mutagenesis 
 The first step in engineering a mutant protein that can better recognize a specific 
chemical involves a different kind of characterization.  The two general approaches to 
protein engineering have generally been used are random and site-directed mutagenesis.  
Random mutagenesis involves introducing mutations at random locations throughout the 
primary structure of the protein.  While this method can give a lot of information, espe-
cially about the effect of certain residues on the kinetics and thermodynamics of protein 
folding, it is very difficult to obtain useful information with regard to binding interactions 
unless the specific mutation has little or no effect on the folding properties and the stabil-
ity of the folded protein and also has some effect on the protein-ligand interface. 
 In contrast, site-directed mutagenesis is much more applicable for engineering 
new or better binding interactions because the method can give much more specific in-
formation related to protein-ligand interactions.  This process involves keeping most of 
the protein sequence constant, as is done with random mutagenesis, and mutating only 
one residue.  The regions of the sequence where mutations are introduced are specifically 
chosen because they have distinct interactions with the particular ligand.  Often these 





 Once a library of mutant proteins has been developed, each one can be compared 
to the wild-type for a multitude of important or useful properties.  For example, when en-
gineering the TetR protein to recognize a new inducer, Scholz, et al.15 were interested in 
which mutations showed high affinity and selectivity for one particular inducer.  In their 
experiments the initial mutations were screened for their affinity to the new inducer and 
tetracycline (Tc); those mutants that did not have relatively high affinity for the Tc analog 
of interest and relatively low affinity for Tc—as compared to the wild-type in both 
cases—could immediately be eliminated.  The mutations that showed both of these prop-
erties were then held constant while a second round of mutagenesis was completed in the 
same regions as before.  Further stages of mutations where then evaluated for their affin-
ity to not only the two compounds of interest, but other Tc analogs.  That way selectivity 
could be defined as a property of a protein such that the protein shows high affinity for 
one particular compound and low affinity for other possible relatives to the compound of 
interest. 
 The same process can be applied to a protein such as MphR(A) even when affin-
ity is not a primary concern and the main purpose is to improve specificity for the pri-
mary inducer.  However, site-directed mutagenesis does require some amount of a priori 
knowledge of how the protein and ligand interact natively.  Since the process requires 
only changing amino acid residues that will have a direct impact on the ligand binding 
and not on the overall folded structure of the protein, it is important to know which resi-
dues should not be changed.  In particular for proteins in the TetR family, it is important 
to hold the DNA-binding region constant so that improved specificity does not come at 




 The easiest way to determine which residues are viable options for mutation will 
be to obtain a crystal structure of the protein, especially if co-crystallization with the tar-
get ligand can be accomplished.  However, if this information is unavailable, a number of 
other proteomic methods can be used in concert to discern the desired information.  Spe-
cifically, by comparing the sequence to that of other proteins with similar function for 
which the crystal structure has been solved, the region of the MphR(A) involved in DNA 
binding can be approximated by the homology of the helix-turn-helix motif.  By holding 
these residues constant, large-scale site direction can be completed to find a set of resi-
dues that are primarily responsible for ligand binding by simply investigating whether or 
not the ligand still binds to the protein after a particular mutation. 
 When engineering the binding pocket of an effector-responsive protein such as 
MphR(A) it is important to maintain most of the structural features of the protein.  Since 
binding of the effector molecule is directly linked to binding or release of DNA, some 
allosteric change is involved16-18.  Thus, it is important for a changed interaction with the 
drug to improve specificity but also maintain transmission of the allosteric information 
through to the DNA-binding domain.  That is, even though a mutation may cause the pro-
tein to bind more specifically to one particular compound, if that mutation and subse-
quent binding does not also cause a change in the DNA-binding characteristics it is essen-
tially useless for further feedback loop engineering. 
1.6: Summary and Study Goals 
 Beginning with the basic characterization of the protein, there are clearly a num-
ber of steps in the process of designing a positive feedback loop using MphR(A) as the 




tionships between the protein and itself (oligomeric form), the DNA sequence it recog-
nizes, and the specific inducer must all be quantified.  Then, the sequence of the protein 
must be analyzed in some way so as to determine which residues, when mutated, will 
have a direct impact on the affinity and specificity for the inducer alone.  Finally, a li-
brary of mutations must be analyzed to determine which mutant gives the highest sensi-
tivity to one particular inducer alone and thus will be the mostly likely to show bistability 
as part of a positive feedback loop.  When combined, all of these steps will provide the 




Chapter 2: Materials and Equipment 
2.1: Materials 
2.1.1: Chemicals and Plasmids 
Table 2-1: List of Reagents 
Chemical Supplier 
AG® MP-1 200-400 mesh chloride form analytical grade 
macroporous anion resin 
BioRad 
CloneJET™ PCR Cloning Kit Fermentas Life Sciences 
GeneJET™ Plasmid Miniprep Kit Fermentas Life Sciences 
Index Sparse Matrix Screens 
 Polyethylene glycol (PEG) 3350 
Hampton Research 
LB (10 g tryptone, 5 g yeast extract, 10 g NaCl / 1 L) FisherBiotech 
M9 Minimal Salts (6 g Na2HPO4, 3 g KH2PO4, 1 g NH4Cl, 
0.5 g NaCl / 1 L) 
US Biological 
QIAquick Gel Extraction Kit Qiagen 
SOC (20 g tryptone, 5 g yeast extract / 1 L + 10 mM NaCl, 25 
mM KCl, 10 mM MgCl2, 20 mM glucose 
FisherBiotech 
Superdex™ 200 prep grade gel filtration resin GE Healthcare 
Wizard™ I and II Sparse Matrix Screens Emerald BioStructures 
Wizard® Plus Midipreps DNA Purification System Promega 
 
Table 2-2: List of Plasmids 
Name Assembled/Provided By Vector/Restriction Map 
p22-CATUPP Prof. Ashton Cropp  
pACYC184/PlacIq-
MphR 




Name Assembled/Provided By Vector/Restriction Map 






























































































































pBAD/mycHisA Novagen  










pBB/PlacIq-MphR Prof. Ashton Cropp 
pBB/PlacIq-MphR
2476 bp












Name Assembled/Provided By Vector/Restriction Map 
































pBB/PmphR-GFPuv Prof. Ashton Cropp  















































































pET28b/NadE Prof. Barbara Gerratana  
pKQ/UPP Prof. Ashton Cropp  
pRK793 Dr. David Waugh  



















 Oligonucleotides used for PCR amplification of genes and circuit components 




periments were purchased from Invitrogen with end modifications as described (Table 2-
3). 
 
Table 2-3: List of Oligonucleotides 
Name Sequence Use Modifications 




Brick™ end to mphR 
gene, Reverse 
Nonei 
CL350 AAAGAATTCG CGGCCGCTTC 
TAGATGATAG ATCCCGTCGT 
TTTACAACG 
LacZ reporter with Bio-
Brick™ ends, Forward 
Noneii 
CL351 TTTCTGCAGC GGCCGCTACT 
AGTTTATTTT TTGACACCAG 
ACCAACTGG 
LacZ reporter with Bio-
Brick™ ends, Reverse 
Noneiii 
CL353 TTTCTGCAGC GGCCGCTACT 
AGTACTCCTG AGGGCTTGAC 
GGG 




CL476 CTGCCTCATC GCTAACTTTG C MphR operator, Forward 5’-Fluorescein 
CL640 CTGCCTCATC GCTAACTTTG C MphR operator, Forward 5’-Biotin 
CL652 TGCCGGATTG AATATAACCG 
ACGTGACTGT TACATTTAGG 
TGGC 
Minimal MphR operator, 
Forward 
None 
CL653 GCCACCTAAA TGTAACAGTC 
ACGTCGGTTA TATTCAATCC 
GGCA 
Minimal MphR operator, 
Reverse 
None 
                                                 
i Red text denotes PstI restriction site. 
ii Green text denotes XbaI restriction site. 




Name Sequence Use Modifications 




Introduction of TEV Pro-
tease recognition se-




2.1.3: Competent Cells 
Table 2-4: List of Competent Cells 
Cell Line Features Competency 
BL21(DE3) Chromosome carries a gene for the expression 
of T7 RNA Polymerase that is IPTG-inducible 
Chemical competent 
Ermr, UPP UPP gene is knocked out of the chromosome.  
Cells were made resistant to erythromycin by 
being grown in increasing concentrations of the 
antibiotic 
Chemical competent 
Mach1 High transformation efficiency Chemical competent 
NEB Turbo Extremely high transformation efficiency Chemical competent 
Rosetta Carries an additional plasmid that confers 
chloramphenicol resistance and expresses addi-
tional tRNA for rare E. coli codons. 
 
UPP UPP gene is knocked out of chromosome Chemical competent 
XL-1 Blue Poor viability for use in blue/white screening Electrocompetent 
 
 
                                                 





Table 2-5: List of Equipment 
Unit Function Manufacturer 
Avanti® J-E Centrifuge 
 JA-20 and JLA-
9.1 Rotors 
Large-scale ( 10 mL) centrifu-
gation 
Beckman Coulter 
Axima-CFR Mass Spectrometry Shimadzu 
BioLogic Duo Flow FPLC Pump BioRad 
BioMax 5K Ultrafree Small-scale ( 2 mL) protein 
concentration 
Millipore Corporation 
Centrifuge 5415 D Small-scale ( 1.5 mL) centrifu-
gation 
Eppendorf 
F-4500 Fluorescence Spectrophotometer Hitachi 
HiLoad™ 16/60 Column FPLC column GE Healthcare 
iCON™ Concentrators, 
7mL/9K 
Large-scale (>2 mL) protein 
concentration 
Thermo Scientific 
IEC Clinical Centrifuge Medium-scale (between 1.5 and 
10 mL) centrifugation 
International Equipment 
Co. 
ImageJ 1.37v DNA image analysis and quanti-
fication 
http://rsb.info.nih.gov/ij/ 







PowerPac Basic Electrophoresis power supply BioRad 
Prism 4.03 Nonlinear regression modeling GraphPad Software 
PTC-200 Peltier Thermal Cycler MJ Research 
Select™ Series UV 
Transilluminator 
Ethidium-stained DNA gel visu-
alization 
Spectroline 
Sonifer 450 with mi-
crotip 




Unit Function Manufacturer 
STORM 850 Scanner Fluorescent Imaging Molecular Dynamics 
Varian 50 Bio UV/Vis Spectrophotometer Cary 




Chapter 3: Characterization of MphR(A) 
3.1: Expression 
 Initially, expression of MphR utilized the arabinose-inducible pBAD promoter.  
However, time course studies of MphR levels following induction showed less than ideal 
expression.  It was determined that an even stronger promoter, particularly one for the T7 
bacteriophage RNA polymerase, was necessary for efficient overexpression of the pro-
tein.  The pET28b expression system contains a T7 promoter upstream of a multiple clon-
ing site consisting of NcoI and HindIII sites, among others.  The mphR gene was ex-
tracted from the pBAD/MphR plasmid with 5’-NcoI and 3’-HindIII overhangs.  The 
sticky ends were then ligated into the expression plasmid. 
 The pET expression system also requires a source of T7 RNA polymerase for 
transcription.  This was achieved by transforming the plasmid into BL21(DE3) chemi-
cally competent cells.  The BL21 cell line contains the gene encoding T7 RNA poly-
merase transfected onto the chromosome under control of a lacUV5 promoter, which al-
lows for induction upon the addition of IPTG.  Once the cells with the correct plasmid 
were available, the conditions for overexpression were optimized.  It has been shown that 
optimal induction takes place when the inducer is added while the growth is still in the 
log phase.  The log phase was reached by growing 50-100 mL overnight and using it to 
inoculate a larger (1.5-2 L) culture which is allowed to grow until OD600 is between 0.5 
and 1.  When using the pBAD system, the optimal induction time is approximately 4 




 It was found that expression in the initial stages after induction is relatively slow; 
up to 6 hours after addition of IPTG, the amount of MphR is not significantly greater than 
other soluble proteins (Figure 3-1).  However, cultures induced overnight generally pro-
duced enough protein to be purified using the incorporated His-tag.  The presence and 
molecular weight of MphR was confirmed by mass spectrometry (Figure 3-2), where the 
monomeric mass was shown to be 22.5 kDa. 
 
3.2: Purification 
 The mphR gene originally used in the pBAD and pET systems contains a C-
terminal His-tag, primarily for purification purposes.  The total volume of soluble pro-
teins from an expression cultures was mixed with Ni2+ resin and increasing concentra-
tions of imidazole were used to wash away non-tagged proteins and eventually elute the 
MphR.  SDS-PAGE confirmed the overexpression and purification of MphR using this 
method (Figure 3-3). 
Figure 3-1: Time-Course Studies of mphR Expression Using pBAD and pET28b Vectors 
(a)  (b)  
Panel (a): SDS-PAGE gel showing soluble proteins of pBAD/MphR cells induced at 37, 30 
and 27 °C for 4, 6, and 24 hours each, from left to right. 
Panel (b): SDS-PAGE gel showing soluble proteins of pET28b/MphR cells induced at 37 °C 







 While the protein is pure enough for biochemical studies, it has been shown that 
one Ni2+ purification is insufficient for crystallography studies; at least one additional 
step must be incorporated prior to crystallization.  The additional purification techniques 
might include ion exchange and size exclusion chromatography, both of which have been 
experimented with for this process.  Early attempts at ion exchange chromatography 
yielded valuable information and promising results (Figure 3-4), but the optimization 
process was stopped short in favor of better alternatives. 
Figure 3-2: MphR Mass Spectrum 
 
MphR peak is at 22492.4 m/z.  Apomyoglobin reference peak is at 16952.3 m/z 
Figure 3-3: MphR His-tag Purification 
 
SDS-PAGE gel showing very large 




 Most crystallography studies simply use FPLC size exclusion chromatography as 
a clean-up technique.  It was determined that purification efforts would be focused on 
optimizing this method.  A chromatogram overlaid with column standards (Figure 3-5) 
shows an aggregated protein peak that eluted off the column very quickly, and a purified 
protein peak between 23 and 49 kDa.  This was reasonable based on the assumption that 
MphR exists in a state of monomer-dimer equilibrium and would run at the oligomeric 
weighted average between 22.5 and 45 kDa. 
 
 
Figure 3-4: MphR Ion Exchange Purification 
 
SDS-PAGE gels showing each 1-mL fraction collected.  In both panels, FT1-9 are 
the fractions collected from the initial protein solution washed over the column.  
Numbered fractions correspond to washes with the appropriate salt concentration 
(50, 200, 500, and 1000 mM NaCl, respectively). 
Figure 3-5: MphR Size Exclusion Purification 
 
FPLC chromatogram overlaid with column standardization. 




3.3: Binding Interactions 
 A variety of methods were tested to quantify the interactions between MphR and 
the operator sequence and between MphR and the inducer erythromycin.  These methods 
included agarose and polyacrylamide gel electrophoresis and fluorescence spectroscopy 
described as follows. 
3.3.1: MphR-DNA Binding Gel-Shift Experiments 
 Two different gel-shift methods were used to determine the equilibrium dissocia-
tion constant, KD, for the binding of MphR to the operator DNA sequence, as determined 
by Noguchi, et al.  For both horizontal agarose and vertical polyacrylamide gel electro-
phoresis, different concentrations of pure protein were combined with a short DNA frag-
ment and run on the gel.  The DNA fragment used was approximately 100 base pairs—
long enough to be seen on the gel, but short enough to show a significant shift when 
bound to the protein—and end modified with a fluorophore or biotin, depending on the 
visualization method to be used.  By determining the amount of DNA in each band 
(bound and unbound), it was possible to determine the fraction of DNA bound for each 
concentration of MphR. 
 The data was then fit to a curve which provided a value for the dissociation con-
stant and confirmation of the coupled equilibria between MphR oligomerization and 
DNA binding.  The Hill equation was used based on the assumption that MphR exists as 
a monomer in solution, but the active form is a dimer.  Thus, some amount of coupling 
must exist. 
 The first set of experiments used a fluorophore-modified DNA strand, which was 




reaction mixtures were run on both 8% polyacrylamide and 3% agarose gels.  The poly-
acrylamide gels were imaged using a Storm scanner, but were difficult to interpret (Fig-
ure 3-6).  However, the same reactions visualized well on agarose gels, which provided 
initial values for the constants; the apparent KD from this data was 0.2 M.  This data is 
shown in more detail in Appendix A. 
 
 There were some drawbacks to using 3% agarose gels: (1) while easy to work 
with, the high percentage of agarose affected the light refraction during imaging, and (2) 
visualization required ethidium intercalation, which in turn required very concentrated 
DNA and protein solutions.  Unfortunately, the short DNA fragments used required a 
high-percentage gel for efficient separation.  Therefore, efforts were made to avoid using 
agarose gels for further experiments. 
 The second set of binding experiments used biotin-modified DNA, which was 
generated by PCR using primers CL640 and CL353 with pTZ3509 as the template.  Be-
cause of the high affinity of streptavidin to biotin, visualization by streptavidin probe 
would require a much smaller amount of protein.  The reaction mixtures were run on 8% 
Figure 3-6: MphR-DNA Binding Gel-Shift Experiment; Fluorescent Label Imaging 
 





polyacrylamide gels and cross-linked to a membrane in a procedure similar to Southern 
blotting.  However, the procedure proved to be difficult to work with for double-stranded 
DNA molecules and it was unclear whether any DNA was transferred to the membrane. 
 The same polyacrylamide preparation was stained with ethidium bromide solution 
and conveniently produced clear bands (Figure 3-7).  The intensity of each band (bound 
and unbound) was found and converted to fraction bound for each protein concentration; 
lanes where the complex did not run at all were assumed to be in a bound state although 
some higher-order protein interactions are obviously at work.  Based on this data, KD was 
found to be 1.9 M with the appearance of extremely cooperative binding.  It was incor-
rect to assume that this data is accurate, unfortunately.  What is clear, however, is that 
significantly more points that show intermediate fractions bound are necessary to deduce 
true values. 
 
Figure 3-7: MphR-DNA Binding Gel-Shift Experiment; Ethidium Bromide Staining 
(a) (b)
MphR-DNA Binding




























Panel (a): 8% polyacrylamide gel visualized with UV transilluminator. 
Panel (b): The data was plotted as fraction bound vs. [MphR], in M.  The DNA concentration 



















 At the writing of this thesis, it was known that similar experiments would have 
given an apparent KD for the binding of the MphR-DNA binding complex to erythromy-
cin and the subsequent release of DNA from the complex.  However, the experiments had 
not yet been completed. 
3.3.2: MphR-DNA Binding Fluorescence Quenching Experiments 
 The intrinsic fluorescence of proteins is primarily due to the tryptophan residues 
and minimally due to tyrosine residues; there are three of each in the MphR primary se-
quence.  Since these residues are aromatic, they are generally found in the interior of a 
folded protein, and often in the ligand-binding pocket, especially for interactions with 
DNA.  Upon binding, the environment of the residues specifically involved—and there-
fore the fluorescence—changes and can be indicative of the amount of protein bound.  
For fluorescence quenching experiments, it was important to decrease the effect of DNA 
absorbance on the spectroscopy, so a minimal operator was prepared by mixing comple-
mentary oligonucleotides. 
 The ds-DNA was titrated into buffer containing 3 M MphR and the fluorescence 
emission spectrum was measured at each concentration (Figure 3-8).  The excitation 
wavelength was 285 nm and the emission maximum was 330 nm.  The data was fit to a 
simple binding model, which suggested an apparent KD on the order of 0.5 M.  It was 
also clear from the residuals of the fit that the model was altogether too simple and sig-
nificantly more data would be necessary to completely understand the biophysical inter-
actions involved in the complex binding system.  At the writing of this thesis, the addi-






3.4.1: Initial Solvent Screening 
 Protein that was purified over Ni2+ resin and AG MP-1 anion exchange resin was 
concentrated to ~10 mg/mL in buffer containing 50 mM Tris and 300 mM salt.  The con-
centration resulted in approximately 200 L solution, which was sufficient to prepare 
crystallography screens with two complete sparse matrix systems: Wizard I and II and 
Index.  The results from these screens (Figure 3-9) were inconclusive directly, but pro-
vided extremely promising results for future screens. 
 The precipitation patterns observed in about 75% of the solvents was indicative of 
two likely explanations: (1) reducing agent was not present in the protein solution and (2) 
higher order aggregates were present in the solution.  Additionally, the high percentage of 
precipitated solutions suggested that the protein was not so soluble that it would remain 
in solution regardless of the solvent used.  Further screens will be conducted following a 
Figure 3-8: MphR-DNA Binding Intrinsic Fluorescence Experiment 
(a)
Fluorescence Quenching




























Panel (a): Fluorescence Intensity vs. [dsDNA].  The [MphR] monomer concentration was 3 
M.  The line represents the fit of a simple one-site model. 




round of size exclusion and in the presence of a reducing agent—which will eliminate the 
aggregated protein and most of the precipitation.  However, it was also found that after 
two months, one of the mixtures in the Index screen had grown very small crystals in so-
lution containing 0.1 M sodium acetate trihydrate, and 25% PEG 3350. 
 
3.4.2: Incorporation of the Tobacco Etch Virus Protease Recognition Sequence 
 In order to minimize the effect of the flexible His-tag, the mphR gene was redes-
igned such that the tag constituted the N-terminal residues.  These residues were sepa-
rated from the start of the protein primary structure by the recognition sequence of the 
tobacco etch virus (TEV) protease.  The TEV protease was chosen because of its ex-
tremely high specificity for the given sequence and due to the fact that it leaves a single 
glycine residue scar, which should not affect the folding of the protein.  The protease was 
also readily available because it could be obtained through overexpression procedures 
similar to those used for MphR using the pRK793 plasmid expressed in Rosetta cells.  





The new mphR gene (Figure 3-10) was generated by PCR and cloned into the pET28b 
multiple cloning site. 
 






The residues shaded light blue are those cut out by the TEV Protease.  The 




Chapter 4: Circuit Engineering 
4.1: General Design 
 Some basic feedback loops that take advantage of the high specificity of the 
MphR-binding DNA sequence have been prepared.  In the work described here, all of 
these circuits involved the expression of MphR on one plasmid and the expression of a 
reporter gene on another.  The design of these plasmids made use of the classic 1.0 Bio-
Brick™ format that incorporates EcoRI, NotI, and XbaI restriction sites to the 5’-end of 
each component and SpeI, NotI, and PstI restriction sites to the 3’-end.  A vector based 
on pKQ—called pBB in this thesis—was used for high-copy pieces and a vector based on 
pACYC184 was used for low-copy pieces. 
 For the feedback loops, a variety of reporter proteins were available.  These pro-
teins include GFPuv, CATUPP, and LacZ, among others.  Expression of the reporter pro-
teins were controlled by the MphR promoter, PmphR, as determined by Noguchi, et al.3  
Expression of the MphR protein was controlled by a variety of promoters—PlacIq and 
PmphR—in the BioBricks construct.  Alternatively, in some cases, the arabinose-inducible 
pBAD/MphR plasmid was used for overexpression of the gene. 
 Some of the components had been previously cloned into one of the two vectors.  
In particular, the plasmids pBB/PmphR, pBB/PlacIq-MphR, pBB/PmphR-MphR, pBB/PmphR-
CATUPP, and pACYC184/PmphR-GFPuv were already assembled.  The first circuits as-
sembled combined pACYC184/PmphR-GFPuv with each of the two pBB/P-MphR plas-




peared to be affected by the presence of MphR (Figure 4-1); however, quantification of 
the fluorescence would require the use of flow cytometry and has not yet been pursued. 
 
 The copy number of each plasmid in the circuit could potentially have a very 
large impact on the output of the reporter alone and the whole circuit.  The high-copy 
GFPuv reporter plasmid (pBB/PmphR-GFPuv) had been previously assembled, but it was 
necessary to assemble the low-copy MphR expression plasmids pACYC184/PlacIq-MphR 
and pACYC184/PmphR-MphR.  Once built, the high-copy reporter was combined with 
each low-copy MphR plasmid and the p22/CATUPP plasmid as a negative control.  
However, the same problem with quantification requiring flow cytometry was still pre-
sent, so these circuits have not yet been studied in great detail. 
 Expression of the CATUPP gene confers resistance to chloramphenicol and sensi-
tivity to 5-fluorouracil, making the latter compound toxic.  The reporter could be quanti-
fied by measuring the growth rate of cell cultures in the presence of each compound.  
Cells that expressed the gene would grow more quickly in the presence of chlorampheni-
col than cells that do not express the gene; conversely, expression of the gene would also 
prevent the cells from growing in the presence of 5-fluorouracil, while cells not express-





ing the gene would grow.  The upp gene is generally found on the chromosome of stan-
dard E. coli, so the use of CATUPP reporter required UPP-knockout (UPP) cells.  Ex-
pression of the lacZ gene produces an enzyme, -galactosidase, for which there is a well-
established assay. 
 Circuits were assembled with both pBB/PmphR-CATUPP and pACYC184/PmphR-
CATUPP.  Each reporter was paired with both MphR expression plasmids on the oppo-
site vector and the appropriate negative control.  A series of different methods were tried 
in building the LacZ circuits.  First, the alpha fragment was generated by PCR and cloned 
downstream of the MphR promoter in the pBB plasmid.  However, the output of this par-
ticular reporter was lower than expected, which may have been related to the relatively 
weak promoter rather than poor enzyme activity.  Regardless, the full-length gene was 
prepared by PCR and cloned into the pJET vector using the CloneJET™ kit.  The result-
ing plasmid was used for months in the attempts to assemble the reporter plasmids, but on 
later evaluation turned out to be incorrect (Figure 4-2).  Then, the lacZ gene was cut out 
of the pBAD/LacZ plasmid and cloned into the low-copy reporter plasmid downstream of 
the MphR promoter sequence. 
 It was important to use the low-copy reporter plasmids because expression of 
MphR on this plasmid was not significant enough to trigger a significant change in the 
expression of the reporter gene.  High levels of MphR could be achieved by using one of 
the overexpression plasmids, but both of those systems could only be paired with pA-
CYC184 reporters.  These systems showed a distinct change in expression levels upon 
addition of MphR; the downside of using them was that initial reporter levels were also 





 Based on the difficulty measuring CATUPP expression in circuits where the 
mphR gene was in a pBB vector, the LacZ circuits were assembled using pBAD/MphR 
for mphR expression.  As a control, the pBAD/mycHisA plasmid—from which 
pBAD/MphR was originally assembled—was included.  That way, all circuits would be 
resistant to ampicillin and tetracycline. 
4.2: Reporter Quantification 
4.2.1: GFPuv Expression Circuits 
 As noted above, the quantification of GFPuv expression generally requires flow 
cytometry.  As the equipment necessary for that procedure was not readily available, the 
GFPuv circuits were assembled and stored for potential future quantification while more 
easily quantifiable circuits were developed and explored. 
 
Figure 4-2: Agarose Gel Showing pJET1.2/LacZ Digested with BglII 
 
Miniprepped plasmid DNA from 8 colonies on the plate of transformed 
ligation reactions was digested with BglII.  The two correct fragments 
were 2.9 and 3.1 kb.  Originally, Colony 4 was selected, but further 




4.2.2: CATUPP Expression Circuits 
 Once the pBB/PmphR-CATUPP reporter plasmid and the pBB/PmphR control plas-
mid had been transformed into UPP cells, they were grown on LB-Agar plates contain-
ing increasing amounts of chloramphenicol to approximately determine the level of resis-
tance.  It was shown that the reporter plasmid was resistant to chloramphenicol up to 700 
g/mL, depending on cellular concentration at the time of plating, while the control 
plasmid did not grow in any amount of antibiotic.  The cells were also grown on M9-
Agar (see Table 6-1) plates containing increasing amounts of 5-fluoruracil to approxi-
mately determine the level of toxicity.  It was shown that 5-fluorouracil was not toxic to 
cells with the control plasmid—that did not express CATUPP—up to 5 g/mL, depend-
ing on cellular concentration at the time of plating, while the nucleotide was immediately 
toxic to cells expressing the gene.  Appendix A, below, contains pictures of these plates. 
4.2.3: LacZ Expression Circuits 
 -Galactosidase activity—and therefore LacZ expression—was measured using 
the Miller assay.  The -galactosidase enzyme hydrolyzes -galactosides into a monosac-
charide and an alcohol.  When o-nitrophenyl--galactoside is used (Figure 4-3), the alco-
hol released is o-nitrophenol, which is yellow in color and absorbs light readily at 420 
nm.  By measuring the absorbance at that wavelength, the total activity of the culture was 
determined.  The assay accounted for cell density and turnover rate to assign a value on 
the Miller unit scale.  Control cultures that express low levels of LacZ (pUC18) gave val-
ues approximately 300 Miller units.  Cultures that overexpress LacZ (pBAD/LacZ) gave 





 The pACYC184/PmphR-LacZ culture measured 10.1 Miller units; the pBB/LacZ 
culture measured 0.94 Miller units.  When incorporated into circuits, the value for pA-
CYC184/PmphR-LacZ increased to 15.3 ± 7.8 Miller units when paired with pBAD/MphR 
and 35.2 ± 1.0 Miller units when paired with pBAD/control (Figure 4-4).  These values 
represent a significant difference between expression with and without MphR present.  
Unfortunately, difficulty was encountered when attempting to measure the effect of 
erythromycin.  Initially, the UPP cells used did not grow in the presence of the antibi-
otic.  However, there was some non-quantitative evidence that introduction of erythro-
mycin did increase LacZ expression (Appendix B).  The circuits were transformed into 
Ermr, UPP cells but appropriate measurements of activity had not been measured as of 
the writing of this thesis. 
 






















































Chapter 5: Summary, Future Work, and Conclusions 
5.1: Summary 
5.1.1: Protein Biochemistry 
 Efficient overexpression and purification of MphR was demonstrated.  Running 
the protein over a Ni2+ resin column produced protein that was over 95% pure and only 
one simple clean-up step (either size exclusion or ion exchange chromatography) was 
necessary to prepare the protein for crystallization studies.  Initial solvent screening pro-
duced extremely promising results, including small crystals in one of the Index solvents.  
The incorporation of a TEV protease recognition site to remove the flexible His-tag was 
also completed successfully.  At present, Jianting Zheng—another member of the re-
search group—has been able to use this construct to grow and purify vast amounts of pro-
tein.  The protein can grow into crystals that diffract x-rays at 2.8 Å resolution. 
 A variety of methods to determine the apparent KD for binding of MphR to DNA 
were investigated, including gel-shift and intrinsic fluorescence quenching experiments.  
For gel-shift experiments, a variety of visualization methods were also tested.  The results 
were generally difficult to interpret, but appeared to give reasonably consistent values for 
the KD around 1 M. 
5.1.2: Circuit Assembly and Quantification 
 Circuits were assembled using a wide variety of the myriad of possible combina-
tions.  The circuits utilized the two-plasmid approach with mphR on one plasmid and the 
PmphR-[reporter] construct on the other.  GFPuv was used as a reporter on both plasmids, 




copy plasmid, but circuits with mphR on the low-copy plasmid did not show a demon-
strable difference in reporter expression.  LacZ was expressed on the low-copy plasmid 
and saw expression decrease by approximately 50% in circuits containing MphR, as 
compared to control circuits. 
5.2: Future Work 
5.3.1: Protein Biochemistry 
 The incorporation of the TEV protease recognition site into the mphR gene should 
allow for improved protein purification without the use of size exclusion chromatogra-
phy.  Since the protease itself carries a His-tag, that enzyme and all other proteins that 
bind non-specifically should stick to the Ni2+ resin while cleaved MphR flows through.  
Once large amounts of pure protein are obtained, further crystallization screens can be 
completed.  A “hit” will provide a solvent for larger-scale crystal growth and subsequent 
x-ray scattering experiments.  Obtaining crystal structures for the protein alone and 
bound to erythromycin is crucial for site-directed mutagenesis to improve inducer speci-
ficity and should be completed soon. 
 In addition to a crystal structure, more detailed biophysical information is neces-
sary to improve inducer specificity.  It will be important to understand the basal affinities 
for various inducers of the wild-type protein before comparing the affinities of mutants.  
Thus, it may be necessary to ascertain binding constants for more complex interactions 
than what was explored in the work presented here.  In particular, the state of the mono-
mer-dimer equilibrium should be understood.  That information will assist in the genera-
tion of an appropriate model for protein-DNA binding interactions, as well as the poten-




5.3.2: Circuit Assembly and Quantification 
 The effect of erythromycin on reporter expression needs to be quantified.  It is 
unclear whether Ermr, UPP cells will allow for any significant uptake of erythromycin 
in addition to resistance.  Expression of the circuits in erythromycin-sensitive cells could 
potentially provide the desired information.  Additionally, it may be of interest to quan-
tify more than one reporter, even though lacZ expression is clearly the simplest and most 
direct. 
5.3.3: Circuit Optimization Using Protein Engineering 
 Since the ultimate goal of the entire project is to design a biofeedback system that 
is extremely sensitive to erythromycin only, a certain amount of protein engineering must 
be used.  As stated above, obtaining a crystal structure of the inducer binding pocket and 
understanding the affinity to the inducer are two key intermediates in this process.  It is 
also important to understand the nature of the wild-type protein in the feedback loops.  
Once structural and biochemical information is obtained, however, it will be a relatively 
simple exercise to engineer optimized MphR mutants. 
 Site-directed mutagenesis can be focused on the region surrounding the inducer 
binding pocket.  Rather than having to express the mutants and analyze their biochemical 
interactions, the mutated plasmid (since mutations take place at the genomic level) can 
simply be incorporated into the established feedback loops for screening.  Those mutants 
that show an increased sensitivity to erythromycin—that is, a smaller amount of erythro-
mycin is required for full reporter expression—will be easily identifiable.  Similar com-






 The work for this thesis produced sufficient demonstrable results: significant pro-
gress was made towards developing quantifiable circuits.  It was found that the various 
biophysical constants associated with MphR are more complex than originally antici-
pated; understanding the oligomeric state of the protein is crucial to modeling all other 
interactions.  A great amount of headway was also made with regards to finding a crystal 
structure of the important allosteric states.  A wide variety of biofeedback loops were as-
sembled with different reporters and quantification of the effects of MphR on reporter 
expression was begun.  The circuits expressing the lacZ reporter gene are very promising 




Chapter 6: Methods 
6.1: Protein Expression 
 For all inducible protein expressions, an overnight culture of 50 mL LB broth 
containing the appropriate antibiotics (100 g/mL ampicillin for pBAD and pRK vectors, 
50 g/mL kanamycin for pET vectors, and 35 g/mL chloramphenicol for vectors ex-
pressed in Rosetta cells) was used to inoculate a 2-L LB culture also containing the ap-
propriate antibiotics.  The large culture was grown until the log phase was reached and 
the appropriate inducer (0.2% arabinose for pBAD vectors and 1 mM IPTG for pET and 
pRK vectors) was added when the OD600 reached 0.8. 
 When using the pBAD expression system, the culture was incubated with shaking 
at 37 °C for 6 hours.  The pET28b expression system required incubation at 37 °C over-
night, while the pRK (Rosetta) vector was incubated at 30 °C for 6 hours in order to 
maximize the amount of soluble protein.  Once the incubation was complete, the cells 
were pelleted by centrifugation at 5,000 rpm for 20 minutes.  At that stage, the pellet 
could either be stored at -80 °C or immediately lysed for protein purification. 
 
Table 6-1: Buffer Compositions 
Buffer Composition 
Binding Buffer 50 mM Tris (pH = 7.9) 
300 mM NaCl 






Wash 40 Buffer 50 mM Tris (pH = 7.9) 
300 mM NaCl 
40 mM imidazole 
10% glycerol 
Wash 50 Buffer 50 mM Tris (pH = 7.9) 
300 mM NaCl 
50 mM imidazole 
10% glycerol 
Wash 60 Buffer 50 mM Tris (pH = 7.9) 
300 mM NaCl 
60 mM imidazole 
10 % glycerol 
Elution Buffer 50 mM Tris (pH = 7.9) 
300 mM NaCl 
300 mM imidazole 
10% glycerol 
Permeabilization Solution 100 mM Na2HPO4 
20 mM KCl 
2 mM MgSO4 
0.8 g/mL hexadecyltrimethylammonium bromide (CTAB) 
0.4 g/mL sodium deoxycholate 
5.4 L/mL -mercaptoethanol (BME) 
Substrate Solution 60 mM Na2HPO4 
40 mM NaH2PO4 
1 mg/mL o-nitrophenyl--D-Galactoside (ONPG) 
2.7 L/mL BME 





10X T4 DNA Ligase Re-
action Buffer 
500 mM Tris (pH = 7.5) 
100 mM MgCl2 
10 mM adenosine triphosphate (ATP) 
100 mM dithiothreitol (DTT) 
M9 Minimal Media 1X M9 Minimal salts 
0.4% glucose 
0.2% casamino acids 
AP 7.5 100 mM Tris (pH = 7.5) 
100 mM NaCl 
2 mM MgCl2 
AP 9.5 100 mM Tris (pH = 9.5) 
100 mM NaCl 
50 mM MgCl2 
 
6.2: Protein Purification 
6.2.1: Ni2+ Resin His-tag Purification 
 The post-induction cell pellet was resuspended in 15 mL Binding Buffer (Table 
6.1) per liter of original culture.  The suspension was frozen completely at -80 °C and 
thawed completely in warm water in two cycles.  This solution was then sonicated at 50% 
output power for 2 minutes in 20-second on/off intervals.  The cell debris was pelleted by 
centrifugation at 15,000 rpm for 45 minutes.  The lysate was then mixed with Ni2+ resin 
(1 mL pelleted resin per 10 mL cell lysate) pre-equilibrated in Binding Buffer and incu-
bated at 4 °C for 2 hours with occasional mixing to bind the protein. 
 Resin bound to the protein was resuspended in the buffer and poured into a glass 




while the buffer flowed through the column.  The binding vessel was rinsed with ~15 mL 
Wash 40 buffer as the initial wash step.  This was followed by five 15-mL washes—2 ! 
Wash 40, 2 ! Wash 50, 1 ! Wash 60.  The protein was eluted using 5 mL Elution Buffer 
for each liter of original culture. 
6.2.2: AG MP-1 Anion Exchange Chromatography 
 The total binding capacity of the resin was 4.2 meq/g dry resin or 1.2 meq/mL 
resin bed.  Based on the theoretical pI of MphR and the pH at which the column would be 
run, it was assumed that each mole of protein would carry four equivalents of charge.  
Thus, 1 gram of dry resin was used for each mmol of protein.  All buffers used for the 
purification contained 250 mM Tris (pH = 7.9).  The resin was equilibrated in buffer con-
taining 50 mM NaCl and the protein was dialyzed into the same buffer.  The protein solu-
tion was poured over the resin and 1-mL fractions (FT) were collected. 
 The various proteins were eluted using washes of 5 mL / mL resin.  The optimal 
purification of MphR was found to take place when the three washes contained 100 mM 
NaCl, 300 mM NaCl, and 1000 mM NaCl, respectively.  With those conditions, the 
MphR primarily eluted in the 300 mM salt fractions, although some protein was lost in 
100 mM fractions and some remained through 1000 mM fractions.  The lost protein was 
not a problem, as long as enough protein was loaded onto the column. 
6.2.3: Superdex™ 200 prep grade Size Exclusion Chromatography 
 Protein previously purified using Ni2+ was concentrated to a maximum of 2 mL.  
The previously packed column was then equilibrated into running buffer that contained 




Rad instrument at 1 mL/min and 2-mL fractions were collected beginning after 37 min-
utes until 143 minutes. 
6.3: Plasmid Generation 
6.3.1: MphR Expression Plasmids 
 The pBAD/MphR plasmid was digested with NcoI and HindIII and the 642-bp 
fragment was extracted from the 1% agarose gel.  The pET28b/NadE plasmid was di-
gested with NcoI and HindIII and the 5246-bp fragment was extracted from the 1% aga-
rose gel.  The two fragments were ligated together and transformed into Mach1 chemical 
competent cells.  The resulting plasmid was named pET28b/MphR. 
 The HisTEVmphR gene was PCR amplified using oligonucleotide primers CL343 
and CL699 and the template pET28b/MphR plasmid.  The product was purified and di-
gested with NcoI and PstI and the 650-bp fragment was extracted from the 1% agarose 
gel.  The pET28b/MphR plasmid was digested with NcoI and PstI and the 5269-bp frag-
ment was extracted from the 1% agarose gel.  The two fragments were ligated together 
and transformed into XL-1 Blue electrocompetent cells.  The resulting plasmid was 
named pET28b/His-TEV-MphR. 
 The pBB/PlacIq-MphR and pBB/PmphR-MphR plasmids were digested with EcoRI 
and PstI and the 689-bp and 792-bp fragments respectively were extracted from the 1% 
agarose gel.  The pACYC184/PmphR-GFPuv plasmid was digested with EcoRI and PstI 
and the 3320-bp fragment was extracted from the 1% agarose gel.  Each insert was 
ligated with the vector and transformed into Mach1 chemical competent cells.  The new 





 The pBB/PmphR plasmid was digested with EcoRI and PstI and the 205-bp frag-
ment was extracted from the 1% agarose gel.  This fragment was ligated 3320-bp pA-
CYC184 vector fragment and transformed into NEBTurbo chemical competent cells.  
The new plasmid was named pACYC184/PmphR. 
6.3.2: Reporter Plasmids 
 The pBB/PmphR-CATUPP plasmid was digested with NotI and the 1477-bp frag-
ment was extracted from the 1% agarose gel.  The pACYC184/PmphR-GFPuv plasmid was 
digested with NotI and SAP and the dephosphorylated 3337-bp fragment was extracted 
from the 1% agarose gel.  The two fragments were ligated together and transformed into 
XL-1 Blue electrocompetent cells.  The new plasmid was named pBB/PmphR-CATUPP. 
 The pBAD/LacZ plasmid was digested with SpeI and PstI and the 3125-bp frag-
ment was extracted from the 1% agarose gel.  The pBB/PmphR plasmid was digested with 
SpeI and PstI and the 3507-bp fragment was extracted from the 1% agarose gel.  The two 
fragments were ligated together and transformed into XL-1 Blue electrocompetent cells.  
The new plasmid was named pBB/PmphR-LacZ. 
 The pBB/PmphR-LacZ plasmid was digested with NotI and the 3284-bp fragment 
was extracted from the 1% agarose gel.  This fragment was ligated with the dephosphory-
lated 3337-bp pACYC184 vector fragment and transformed into XL-1 Blue eletrocompe-
tent cells.  The new plasmid was named pACYC184/PmphR-LacZ. 
 
6.4: LacZ Activity Miller Assay 
 A 2-mL culture of the cells of interest was grown in LB broth with the appropriate 




ture and any additional components (erythromycin, arabinose, etc.) were added.  The new 
culture was incubated at 37 °C until OD600  0.5.  The exact OD600 was measured and 20 
L of the culture was added to 80 L permeabilization solution.  The mixture and sub-
strate solution were incubated at 30 °C for 30 minutes before 600 L of the substrate so-
lution was added to the lysed cells. 
 The reaction was allowed to proceed until a yellow color was observed.  700 L 
of the stop solution was added and the total reaction time, in minutes, was recorded.  The 
reaction mixtures were centrifuged at 13,200 rpm for 5 minutes and the absorbance at 
420 nm was measured of a sample taken from the top of the reaction tube.  The Miller 
units of a particular culture were calculated using Equation 6-1. 
 
Equation 6-1: Miller Units Calculation 




4201000 , where V is the volume of cell culture sampled (0.02 mL) and 
t is the reaction time in minutes. 
 
6.5: Other General Methods 
6.5.1: Gel-shift Binding Experiments 
 Fixed amounts of DNA were mixed with varying amounts of MphR.  Each reac-
tion was diluted to 20 L total volume and incubated at room temperature for 30 minutes.  
4 L of 6X DNA Loading dye containing bromophenol blue and xylene cyanol.  3% aga-
rose gels were run in TAE buffer at 120 V and 8% polyacrylamide gels were run in TBE 




gel.  For staining, the gel was incubated for 1 hour in 200 L of the appropriate buffer 
containing 10 L of ethidium bromide (stock solution of 10mg/mL). 
 Polyacrylamide gels with fluorescent-tagged DNA were scanned directly using 
the Storm scanner.  Biotinylated DNA was transferred to a positively charged nylon 
membrane in a cassette run at 60 V for 20 minutes.  The DNA was cross-linked to the 
membrane under short-wave UV light for 10 minutes.  The membrane was blocked by 
rinsing with 10 mL AP 7.5 buffer + 2% dry milk and incubating at 37 °C for 15 minutes.  
The blocking solution was removed and 10 mL AP 7.5 buffer with 2% dry milk and 5 L 
concentrated streptavidin alkaline phosphatase was added.  That solution was incubated 
room temperature for 90 minutes to bind to the biotinylated DNA.  The binding solution 
was removed the membrane was washed twice with 50 mL AP 7.5 buffer and once with 
50 mL AP 9.5 buffer at room temperature for 10 minutes each.  The membrane was then 
stained with a solution of 20 L nitroblue tetrazolium/5-bromo-4-chloro-3-
indolylphosphate in 1 mL AP 9.5 buffer for 15 minutes in the dark at room temperature.   
6.5.2: Fluorescence Binding Experiments 
 MphR was diluted to 3 M monomer concentration (as determined by A280) in 
buffer containing 50 mM Tris (pH = 7.9) and 100 mM NaCl.  The fluorescence excitation 
spectrum was obtained and the maximum was found at 285 nm.  At 285, the fluorescence 
emission spectrum was obtained and the maximum was found at 330 nm.  Small volumes 
of concentrated DNA were titrated into the protein solution and the emission spectrum at 
each point was obtained in triplicate after allowing the mixture to equilibrate for 2 min-
utes.  The fluorescence intensity at 330 nm was averaged for each DNA concentration. 




 Most PCR reactions were completed as described here.  Minor modifications were 
made as necessary to obtain maximum results.  The reaction mixture was prepared using 
40 L H2O, 5 L 10X ThermoPol buffer, 1 L template, 1 L forward primer, 1 L re-
verse primer, and 1 L 10 mM dNTP’s.  Using a thermo cycler, the following program 
was run: 
1. 95 °C for 3 minutes; 
2. 95 °C for 30 seconds; 
3. 5 °C below the lowest primer TM for 30 seconds; 
4. 72 °C for 15 seconds plus 1 minute per 1000 bases in the product; 
5. Return to step 2 for 29 repetitions; 
6. 72 °C for 3 minutes; 
7. 4 °C for ever. 
 1 L Taq Polymerase was added during the initial heating step at 95 °C.  The 
completeness of the reaction was verified by agarose gel electrophoresis. 
6.5.4: Circuit Assembly and Transformations 
 All chemical transformations were completed using 100 L of flash-frozen 
chemical competent cells mixed with 10 L of each plasmid.  The mixture was incubated 
on ice for 30 minutes followed by 90 seconds at 42 °C and 2 minutes on ice again.  500 
L of SOC media was then added and the culture was incubated at 37 °C for 45 minutes.  
150 L of the culture was then smeared on an LB-Agar plate containing the appropriate 
antibiotic(s) which was then incubated at 37 °C overnight. 
 All electroporations were completed using 50 L of flash-frozen electrocompetent 




2-mm gap electroporation cuvette and shocked using the Ec2 setting of the electropora-
tor.  500 L of SOC media was immediately added and the culture was incubated at 37 
°C for 45 minutes.  150 L of the culture was then smeared on an LB-Agar plate contain-
ing the appropriate antibiotic(s) which was then incubated at 37 °C overnight. 
 The various circuits were assembled by transforming equal amounts of the two 
plasmids simultaneously.  For appropriate reporter expression, all circuits expressing 
CATUPP and LacZ were transformed into UPP cells.  Ultimately, pACYC184/PmphR-
LacZ circuits were transformed into Ermr, UPP cells for measurements of the effect of 
erythromycin on the reporter expression. 
6.5.5: DNA Purification—Phenol/Chloroform Extraction and Isopropanol Precipitation 
 When the denaturation of an enzyme—typically a polymerase used for PCR—was 
necessary, phenol/chloroform extraction was used.  The extraction was always followed 
by isopropanol precipitation.  Water was added to approximately double the volume of 
the DNA solution.  A volume of 1:1 phenol/chloroform mixture pH equilibrated with TE 
buffer equal to the volume of the original DNA solution was added and the mixture was 
vortexed thoroughly for 1 minute.  The sample was then centrifuged at 13,200 rpm for 5 
minutes and the aqueous layer was removed.  A volume of 100% chloroform equal to the 
removed aqueous layer was added and vortexed.  The mixture was centrifuged at 13,200 
rpm for 5 minutes, the aqueous layer was removed and the chloroform steps were re-
peated again.  After finally removing the aqueous layer, the DNA was ready for precipita-
tion. 
 Alternatively, when extraction was not required, the DNA was simply precipi-




isopropanol was added and the mixture was cooled at -20 °C for 1 hour.  The mixture 
was centrifuged at 13,200 rpm for 5 minutes and the supernatant was removed.  The pre-
cipitate was washed with 70% EtOH (H2O), cooled at -20 °C for 10 minutes and centri-
fuged at 13,200 rpm for 5 minutes.  The supernatant was removed and the wash process 
was repeated with 100% EtOH.  The DNA was finally resuspended in a volume of water 
or TE buffer (pH = 8.0) depending on the desired concentration and eventual use. 
6.5.6: DNA Manipulation Methods 
 Plasmid DNA was isolated from cell cultures using either the GeneJET™ Plasmid 
Miniprep kit or the Wizard® Plus Midiprep kit, depending on the culture size and the 
amount of DNA needed.  DNA fragments were extracted from agarose gels using the 
QIAquick Gel Extraction kit.  Ligation reactions were completed by mixing the insert and 
vector in ratios that ranged from 3:1 to 5:1, depending on the fragment sizes.  The DNA 
was mixed together with the necessary volume of water and heated to 85 °C for 10 min-
utes to melt the strands.  The solution was cooled to 4 °C for 30 minutes to anneal the 
strands and sticky ends.  Since all ligations were completed in 20 L reactions, 2 L 10X 
Ligase Buffer and 1 L T4 DNA Ligase were added.  The solution was then incubated at 
16 °C overnight for best results.  A negative control reaction containing more water in-
stead of insert DNA was always completed simultaneously. 
6.5.7: Mass Spectrometry 
 Mass spectra were obtained in linear mode at 90% maximum intensity.  The spec-






Appendix A: MphR-DNA Binding Experiment 
 The fluorescent-labelled DNA-binding gel-shift experiment was difficult to visu-
alize.  Ethidium bromide staining requires a large amount of DNA—more than was pre-
sent in the reaction mixtures—for adequate illumination.  Additionally, the high percent-
age gel increased the diffraction due to the gel.  The two effects combined to result in 
DNA bands that were not significantly darker than the background (Figure A-1) with a 
low signal to noise ratio. 
 
Appendix B: Crude Quantification of CATUPP Expression 
 For chloramphenicol resistance test, LB-Agar plates containing 50 g/mL kana-
mycin and a concentration of chloramphenicol between 0 and 1000 g/mL were pre-
pared.  Cultures of pBB/PmphR-CATUPP (CATUPP) and pBB/PmphR (control) were grown 
Figure A-1: MphR-DNA Binding Gel-Shift Experiment; Agarose Gel 
(a) (b)
MphR-DNA  Binding





























Panel (a): 3% agarose gel visualized with UV transilluminator. 
Panel (b): Data plotted as fraction bound vs. [MphR] in M.  The DNA concen-




in liquid LB with 50 g/mL kanamycin overnight.  A portion of the stationary phase cul-
ture was diluted 10X in liquid LB.  50 L of each culture and each dilution were smeared 
on the chloramphenicol plates and incubated at 37 °C for 48 hours (Figure A-2). 
 
 For 5-fluorouracil toxicity test, M9-Agar plates containing 50 g/mL kanamycin 
and a concentration of 5-fluorouracil between 0 and 10 g/mL were prepared.  Cultures 
of pBB/PmphR-CATUPP (CATUPP) and pBB/PmphR (control) were grown in liquid LB 
with 50 g/mL kanamycin overnight.  1 mL of the stationary phase culture was spun at 
8,000 rpm for 2 minutes and the pelleted cells were resuspended in 1 mL M9 media.  A 
portion of the suspension was diluted 10X in M9 media.  50 L of each culture and each 
dilution were smeared on the 5-fluorouracil plates and incubated at 37 °C for 48 hours 
(Figure A-3). 
Figure A-2: Chloramphenicol Resistance Test 
 
There is no difference between the two panels except for background color.  Clockwise from 
top left: 1000, 700, 500, and 0 g/mL chloramphenicol, respectively.  On all plates, the outer 
smears are from stationary phase cultures and the inner smears are from the dilutions.  On all 





Appendix C: Crude Qualification of the Effect of Erythromycin on LacZ Expression 
 To check the potential effect of erythromycin on LacZ expression, LB-Agar plates 
containing 100 g/mL ampicillin, 10 g/mL tetracycline, 0.2% arabinose, and 4% (v/v) 
X-Gal were prepared.  Additionally, small discs of filter paper were created using a stan-
dard desk hole-punch.  One drop of 100 g/mL erythromycin in 100% ethanol was placed 
on each disc and the ethanol was evaporated, drying the discs. 
 Cultures of pACYC184/PmphR-LacZ + pBAD/MphR (+MphR) and pA-
CYC184/PmphR-LacZ + pBAD/mycHisA (control) were grown in liquid LB containing 
100 g/mL ampicillin and 10 g/mL tetracycline overnight.  100 L of each culture was 
smeared on a plate and the dry erythromycin disc was placed on top in the center of each 
plate, which was then incubated at 37 °C for 48 hours (Figure A-4).  The lawn of blue 
colonies on the control plate demonstrated that LacZ expression was not affected by the 
Figure A-3: 5-Fluorouracil Toxicity Test 
 
There is no difference between the two panels except for background color.  Clockwise from 
top left: 10, 2, 0.5, and 0 g/mL 5-fluorouracil, respectively.  On all plates, the outer smears 
are from stationary phase cultures and the inner smears are from the dilutions.  On all plates, 




introduction of erythromycin in this culture.  Conversely, the ring of more pronounced 
blue colonies near the disc suggested that the presence of small amounts of erythromycin 
increased the density of blue colonies, which signaled an increase in LacZ expression. 
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